The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2022 | How will the MOUNTAINEER trial affect the HER2-positive mCRC treatment landscape?
John Strickler, MD, Duke Cancer Center, Durham, NC, discusses the potential outcomes from the Phase II MOUNTAINEER trial (NCT03043313). There are current no approved agents to treat HER2-positive metastatic colorectal cancer (mCRC), with current therapies in the clinic being administered off-label. Prof. Strickler highlights how the MOUNTAINEER trial will provide a new standard of care for this group of patients. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
